JP2008518902A - 乳癌のためのｃｔｌａ４抗体とアロマターゼ阻害剤の併用治療 - Google Patents

乳癌のためのｃｔｌａ４抗体とアロマターゼ阻害剤の併用治療 Download PDF

Info

Publication number
JP2008518902A
JP2008518902A JP2007538539A JP2007538539A JP2008518902A JP 2008518902 A JP2008518902 A JP 2008518902A JP 2007538539 A JP2007538539 A JP 2007538539A JP 2007538539 A JP2007538539 A JP 2007538539A JP 2008518902 A JP2008518902 A JP 2008518902A
Authority
JP
Japan
Prior art keywords
antibody
seq
amino acid
acid sequence
ctla4
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2007538539A
Other languages
English (en)
Japanese (ja)
Inventor
ゴメズ−ナヴァッロ ジーザス
Original Assignee
ファイザー・プロダクツ・インク
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ファイザー・プロダクツ・インク filed Critical ファイザー・プロダクツ・インク
Publication of JP2008518902A publication Critical patent/JP2008518902A/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2007538539A 2004-11-04 2005-10-24 乳癌のためのｃｔｌａ４抗体とアロマターゼ阻害剤の併用治療 Withdrawn JP2008518902A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US62485604P 2004-11-04 2004-11-04
PCT/IB2005/003307 WO2006048749A1 (fr) 2004-11-04 2005-10-24 Anticorps ctla-4 et inhibiteur de l'aromatase ou traitement combine du cancer du sein

Publications (1)

Publication Number Publication Date
JP2008518902A true JP2008518902A (ja) 2008-06-05

Family

ID=35825412

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007538539A Withdrawn JP2008518902A (ja) 2004-11-04 2005-10-24 乳癌のためのｃｔｌａ４抗体とアロマターゼ阻害剤の併用治療

Country Status (15)

Country Link
EP (1) EP1819735A1 (fr)
JP (1) JP2008518902A (fr)
KR (1) KR20070067702A (fr)
CN (1) CN101052655A (fr)
AR (1) AR053651A1 (fr)
AU (1) AU2005300315A1 (fr)
BR (1) BRPI0515735A2 (fr)
CA (1) CA2586844A1 (fr)
IL (1) IL182244A0 (fr)
MX (1) MX2007003804A (fr)
NO (1) NO20072576L (fr)
RU (1) RU2007114111A (fr)
TW (1) TW200621804A (fr)
WO (1) WO2006048749A1 (fr)
ZA (1) ZA200702577B (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014530235A (ja) * 2011-10-14 2014-11-17 ジェネンテック， インコーポレイテッド Ｈｅｒ２二量体化阻害剤ペルツズマブの使用及びペルツズマブを含む製造品

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2605796A1 (fr) * 2005-04-25 2006-11-02 Pfizer Products Inc. Compositions pharmaceutiques et methodes comprenant une combinaison d'un modulateur selectif du recepteur de l'oestrogene et d'un inhibiteur de l'aromatase
SG163583A1 (en) * 2005-07-07 2010-08-30 Coley Pharm Group Inc Anti-ctla-4 antibody and cpg-motif-containing synthetic oligodeoxynucleotide combination therapy for cancer treatment
US7700567B2 (en) 2005-09-29 2010-04-20 Supergen, Inc. Oligonucleotide analogues incorporating 5-aza-cytosine therein
CA2647282A1 (fr) * 2006-04-05 2007-10-11 Pfizer Products Inc. Polytherapie a base d'un anticorps anti-ctla4
CN101909693A (zh) * 2008-01-08 2010-12-08 百时美施贵宝公司 用于治疗增殖性疾病的抗-ctla4抗体与微管蛋白调节剂的组合
WO2010014784A2 (fr) * 2008-08-01 2010-02-04 Bristol-Myers Squibb Company Combinaison d'anticorps anti-ctla4 avec divers régimes thérapeutiques pour un traitement synergétique de maladies prolifératives
US8829173B2 (en) 2008-09-26 2014-09-09 Tocagen Inc. Recombinant vectors
EA027693B1 (ru) 2008-09-26 2017-08-31 Токаджен Инк. Рекомбинантный репликационно-компетентный ретровирус с цитозиндезаминазной активностью для генной терапии нарушений клеточной пролиферации
WO2010040105A2 (fr) 2008-10-02 2010-04-08 Trubion Pharmaceuticals, Inc. Protéines de liaison multicibles antagonistes de cd86
DK2769737T3 (en) * 2009-07-20 2017-07-24 Bristol Myers Squibb Co COMBINATION OF ANTI-CTLA4 ANTIBODY WITH ETOPOSIDE FOR SYNERGISTIC TREATMENT OF PROLIFERATIVE DISEASES
EP2710137B1 (fr) 2011-03-10 2018-09-19 Provectus Pharmatech, Inc. Une combinaison de rose bengale et un antikorps anti-ctla4 pour le traitement du cancer
KR102004559B1 (ko) 2011-08-30 2019-07-26 아스텍스 파마수티컬스, 인크. 데시타빈 유도체 제제
PE20142406A1 (es) 2012-05-04 2015-01-23 Pfizer Antigenos asociados a prostata y regimenes de inmunoterapia basados en vacuna
CN103768596B (zh) * 2012-10-17 2016-06-22 苏州丁孚靶点生物技术有限公司 用于肿瘤治疗的组合产品、其用途及相关方法
CN104884627A (zh) 2012-10-25 2015-09-02 托卡根公司 具有小型启动子盒的逆转录病毒载体
CN110448566A (zh) 2013-03-01 2019-11-15 阿斯泰克斯制药公司 药物组合
EP3057990B1 (fr) * 2013-10-18 2019-09-04 Regeneron Pharmaceuticals, Inc. Compositions comprenant une combinaison d'antagoniste du vegf et d'anticorps anti-ctla-4
JP6768722B2 (ja) 2015-07-02 2020-10-14 大塚製薬株式会社 凍結乾燥医薬組成物
EA201890640A1 (ru) 2015-09-04 2018-09-28 Токаджен Инк. Рекомбинантные векторы, содержащие пептид 2а
CN106883298B (zh) * 2015-12-16 2021-12-17 上海康岱生物医药技术股份有限公司 双特异性偶联抗体及其制法和用途
SG11201805835WA (en) 2016-01-08 2018-08-30 Replimune Ltd Modified oncolytic virus
US11542332B2 (en) 2016-03-26 2023-01-03 Bioatla, Inc. Anti-CTLA4 antibodies, antibody fragments, their immunoconjugates and uses thereof
JP7461741B2 (ja) 2016-06-20 2024-04-04 カイマブ・リミテッド 抗ｐｄ－ｌ１およびｉｌ－２サイトカイン
JP7198666B2 (ja) * 2016-08-26 2023-01-04 哲治 奥野 微小血管血流低減剤およびその利用
WO2018098352A2 (fr) 2016-11-22 2018-05-31 Jun Oishi Ciblage d'expression du point de contrôle immunitaire induit par kras
HUE064898T2 (hu) 2017-03-02 2024-04-28 Genentech Inc HER2-pozitív emlõrák adjuváns kezelése
WO2018167780A1 (fr) * 2017-03-12 2018-09-20 Yeda Research And Development Co. Ltd. Méthodes de diagnostic et de traitement du cancer
BR112020002280A2 (pt) 2017-08-03 2020-07-28 Otsuka Pharmaceutical Co., Ltd. composto farmacológico e métodos purificação do mesmo
WO2021173870A1 (fr) * 2020-02-27 2021-09-02 University Of Washington Composition et procédé pour préparer une suspension injectable à action prolongée contenant de multiples médicaments anticancéreux

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL149701A0 (en) * 2001-05-23 2002-11-10 Pfizer Prod Inc Use of anti-ctla-4 antibodies

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014530235A (ja) * 2011-10-14 2014-11-17 ジェネンテック， インコーポレイテッド Ｈｅｒ２二量体化阻害剤ペルツズマブの使用及びペルツズマブを含む製造品
JP2017222663A (ja) * 2011-10-14 2017-12-21 ジェネンテック， インコーポレイテッド Ｈｅｒ２二量体化阻害剤ペルツズマブの使用及びペルツズマブを含む製造品

Also Published As

Publication number Publication date
TW200621804A (en) 2006-07-01
CN101052655A (zh) 2007-10-10
MX2007003804A (es) 2007-04-23
AR053651A1 (es) 2007-05-16
ZA200702577B (en) 2008-07-30
IL182244A0 (en) 2007-09-20
CA2586844A1 (fr) 2006-05-11
RU2007114111A (ru) 2008-12-10
NO20072576L (no) 2007-08-03
WO2006048749A1 (fr) 2006-05-11
KR20070067702A (ko) 2007-06-28
BRPI0515735A2 (pt) 2011-10-11
AU2005300315A1 (en) 2006-05-11
EP1819735A1 (fr) 2007-08-22

Similar Documents

Publication Publication Date Title
JP2008518902A (ja) 乳癌のためのｃｔｌａ４抗体とアロマターゼ阻害剤の併用治療
EP2699598B1 (fr) Combinaisons d'anticorps anti-4-1bb et d'anticorps induisant une cytotoxicité à médiation cellulaire dépendante d'un anticorps (adcc) pour le traitement du cancer
AU2005264063B2 (en) Combination treatment for non-hematologic malignancies using an anti-igf-1r antibody
US20090074787A1 (en) Anti-CTLA4 Antibody and Indolinone Combination Therapy for Treatment of Cancer
US20220265844A1 (en) Dosing regimens for anti-tf-antibody drug-conjugates
JP2020510673A (ja) がんの治療のための低分子ｃｓｆ−１ｒ阻害剤とｃｄ４０に特異的に結合するアゴニスト抗体とを含む併用療法
JP2020528061A (ja) ＢＥＴ阻害剤、Ｂｃｌ−２阻害剤及び抗ＣＤ２０抗体を用いた併用療法
JP2021532067A (ja) Ｓｕｍｏ活性化酵素阻害剤及び抗ｃｄ２０抗体の投与
WO2019217455A1 (fr) Méthodes de traitement du cancer à l'aide d'une combinaison d'un anticorps anti-pd-1 et d'un conjugué anticorps anti-facteur tissulaire-médicament
JP2024511478A (ja) 抗ｔｍ４ｓｆ１抗体および免疫療法剤を含む組合せ剤ならびにそれを使用する方法
CN117940452A (zh) 用于治疗癌症的方法和组合物

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20081023

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20081023

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20090105